Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Huizhou
Clinical trial register · China

Clinical Trials in Huizhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19224 matching records held by the registry are in this view. Synced 11 Nov 2026, 03:17 UTC
19224
Studies in scope
all four open statuses
11811
Recruiting now
open to new participants
2030
Lead sponsors
across recruiting studies
Top sites
Beijing 5586 Shanghai 3885 Guangzhou 3356 Hangzhou 1825 Wuhan 1342
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Nanfang Hospital, Southern Medical University8 Guangzhou Medical University7 Janssen Research & Development, LLC5 Pfizer5 Hoffmann-La Roche5
Site location
Beijing5586 Shanghai3885 Guangzhou3356 Hangzhou1825 Wuhan1342
All 625 locations
Target enrolment
to

Trials with a site in Huizhou

83 of 19224 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Pfizer
Phase 3
432
Hefei, Beijing, Huizhou, Zhengzhou, Nanjing, Nanchang
2026-10-28
Recruiting
Hoffmann-La Roche
Phase 3
325
Guangzhou, Mianyang, Changde, Huizhou, Ningbo, Sanmenxia, Shanghai, Xiamen
2026-10-16
Not yet open
Beijing QL Biopharmaceutical Co.,Ltd
Phase 2
210
Beijing, Huizhou, Handan, Langfang, Harbin, Nanyang, Yichang, Changde
2026-10-12
Recruiting
Novo Nordisk A/S
Phase 4
300
Fuyang, Beijing, Lanzhou, Huizhou, Shantou, Shijiazhuang, Anyang, Yichang
2026-10-12
Not yet open
Nanfang Hospital, Southern Medical University
Phase 1/2
49
Hefei, Beijing, Fuzhou, Dongguan, Guangzhou, Huizhou, Maoming, Shenzhen
2026-10-10
Not yet open
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
444
Guangzhou, Huizhou, Jieyang, Zhongshan, Zhuhai, Shanghai
2026-10-01
Recruiting
Pfizer
Phase 3
300
Hefei, Beijing, Chongqing, Huizhou, Hengshui, Shijiazhuang, Harbin, Luoyang
2026-09-24
Recruiting
AstraZeneca
Phase 3
1,500
Beijing, Cangzhou, Changchun, Chengdu, Danyang, Ganzhou, Guangzhou, Huizhou
2026-08-20
Not yet open
Jiangsu Carephar Pharmaceutical Co., Ltd.
Phase 2
156
Beijing, Bengbu, Changsha, Chongqing, Fujian, Guangzhou, Hefei, Huizhou
2026-07-12
Recruiting
Eli Lilly and Company
Phase 2
531
Binzhou, Chengdu, Guangzhou, Hangzhou, Hengyang, Huizhou, Huzhou, Meihekou
2026-05-06
Recruiting
Eli Lilly and Company
Phase 2
60
Changsha, Changzhou, Guangzhou, Hangzhou, Huizhou, Suzhou, Wenzhou, Xiamen
2026-05-04
Recruiting
Eli Lilly and Company
Phase 2
60
Changsha, Changzhou, Guangzhou, Hangzhou, Huizhou, Suzhou, Wenzhou, Xiamen
2026-05-04
Recruiting
Eli Lilly and Company
Phase 2
342
Binzhou, Chengdu, Guangzhou, Hangzhou, Hengyang, Huizhou, Huzhou, Meihekou
2026-04-29
Recruiting
Nanfang Hospital, Southern Medical University
Phase 2
126
Foshan, Gaozhou, Guangzhou, Huizhou, Zhaoqing, Liuzhou
2026-04-01
Recruiting
Hoffmann-La Roche
Phase 3
2,000
Zhenjiang, Xianyang, Jinan, Beijing, Changchun, Hefei, Herbin, Huizhou
2026-03-16
Recruiting
Phase II Study of RC1416 Injection in COPD
NCT07402551Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
DrugRC1416
Nanjing RegeneCore Biotech Co., Ltd.
Phase 2
180
Hefei, Suzhou, Chongqing, Xiamen, Guangzhou, Huizhou, Jiangmen, Qingyuan
2026-03-06
Recruiting
Pfizer
Phase 2/3
1,156
Chizhou, Fuyang, Hefei, Beijing, Chongqing, Guangzhou, Huizhou, Xinxiang
2026-02-11
Recruiting
Sanofi
Phase 3
751
Guangzhou, Huizhou, Shanghai, Wuxi
2026-01-22
Active, closed
Beijing QL Biopharmaceutical Co.,Ltd
Phase 3
755
Xuancheng, Beijing, Chongqing, Lanzhou, Guangzhou, Huizhou, Nanning, Handan
2026-01-16
Recruiting
Sanofi
Phase 3
751
Guangzhou, Huizhou, Wuxi, Chengdu, Beijing, Hefei, Kunming, Shanghai
2026-01-16
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsPF-08634404·Pembrolizumab
Pfizer
Phase 3
1,410
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Huizhou, Jiangmen, Nanning
2026-01-06
Active, closed
DIEP-MDS for Risk Stratification of Flap Vascular Compromise and Failure in Breast Reconstruction
NCT07761390Breast Neoplasms, Breast Reconstruction, Postoperative Complications
Zhuliling
Observational
1,500
Xiamen, Dongguan, Guangzhou, Huizhou, Meizhou, Shantou, Shanwei, Shaoguan
2026-01-01
Recruiting
Guangzhou Medical University
Phase 1/2
34
Huizhou
2026-01-01
Recruiting
Shanghai Zhongshan Hospital
Phase 4
1,316
Hefei, Huizhou, Shenzhen, Harbin, Xinxiang, Wuhan, Changsha, Hengyang
2025-12-13
Recruiting
InSilico Medicine Hong Kong Limited
Phase 2
80
Beijing, Chongqing, Guangzhou, Huizhou, Nanning, Shijiazhuang, Luoyang, Xinxiang
2025-12-10
Recruiting
GlaxoSmithKline
Phase 2
363
Beijing, Chongqing, Dongguan, Guangzhou, Guilin, Hangzhou, Huizhou, Jiangmen
2025-10-30
Recruiting
Sanofi
Phase 3
980
Xiamen, Guangzhou, Huizhou, Shenzhen, Wuhan, Changsha, Nanjing, Wuxi
2025-10-01
Recruiting
Genentech, Inc.
Phase 2
224
Fuzhou, Xiamen, Guangzhou, Huizhou, Zhengzhou, Wuhan, Changchun, Binzhou
2025-09-29
Recruiting
Guangzhou Medical University
Phase 2
36
Huizhou
2025-09-01
Not yet open
Nanfang Hospital, Southern Medical University
Not applicable
110
Guangzhou, Huizhou, Jieyang, Meizhou
2025-09-01
Recruiting
Nanfang Hospital, Southern Medical University
Observational
264
Guangzhou, Huizhou, Jieyang, Meizhou
2025-09
Active, closed
Amgen
Phase 3
12,800
Bengbu, Beijing, Guangzhou, Huizhou, Yulin, Qinhuangdao, Shijiazhuang, Harbin
2025-07-25
Recruiting
Pfizer
Phase 3
714
Hefei, Beijing, Fuzhou, Guangzhou, Huizhou, Nanning, Harbin, Luoyang
2025-07-23
Not yet open
Nanfang Hospital, Southern Medical University
Observational
338
Guangzhou, Huizhou, Meizhou
2025-07-20
Recruiting
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 2
360
Chizhou, Hefei, Lanzhou, Huizhou, Jiangmen, Qingyuan, Zunyi, Langfang
2025-07-15
Active, closed
Sanofi
Phase 2
105
Huizhou, Guangzhou, Nanjing, Suzhou, Wuxi, Shanghai, Hangzhou, Ningbo
2025-07-07
Active, closed
Feasibility of Multi-cancer Early Detection Test in Screening Population (NQMD-CS)
NCT07834268Colorectal Cancer, Grastic Cancer, Esophageal Cancer, Lung Cancer
Fifth Affiliated Hospital of Guangzhou Medical University
Not applicable
1,250
Guangzhou, Huizhou
2025-07-02
Recruiting
Hoffmann-La Roche
Phase 3
425
Ganzhou, Jinhua, Beijing, Chengdu, Guangzhou, Haikou, Huai'an, Huizhou
2025-05-12
Recruiting
BioNTech SE
Phase 1/2
380
Bengbu, Changchun, Chengdu, Chongqing, Huizhou, Nanning, Shanghai, Xi'an
2025-04-23
Recruiting
Shanghai Chest Hospital
Not applicable
162
Shenyang, Shanghai, Huizhou
2025-04-01
Recruiting
Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis
NCT06809517Leptomeningeal Metastasis, Intrathecal Drug Delivery
DrugsPemetrexed·Docetaxel
Guangzhou Medical University
Phase 1/2
34
Huizhou
2025-03-18
Active, closed
Guangzhou Medical University
Phase 1/2
39
Beijing, Huizhou, Shanghai
2025-03-17
Active, closed
Celgene
Phase 3
960
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Huizhou, Changzhou, Nanjing
2025-03-13
Active, closed
Guangzhou Medical University
Phase 1/2
39
Huizhou, Beijing, Shanghai
2025-03-07
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
135
Bengbu, Wuwei, Guangzhou, Huizhou, Harbin, Luoyang, Nanyang, Zhengzhou
2025-01-28
Recruiting
Waterstone Pharmaceutical (Wuhan) Co., LTD.
Phase 3
420
Bengbu, Wuhu, Chongqing, Xiamen, Lanzhou, Guangzhou, Zhanjiang, Huizhou
2024-12-23
Active, closed
Hoffmann-La Roche
Phase 3
350
Beijing, Kunming, Changsha, Chengdu, Guangzhou, Hangzhou, Huizhou, Nanning
2024-12-11
Active, closed
Merck Sharp & Dohme LLC
Phase 3
67
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Huizhou, Jiangmen, Liuzhou
2024-11-21
Recruiting
Janssen Research & Development, LLC
Phase 3
1,000
Beijing, Changchun, Changsha, Guangzhou, Hangzhou, Harbin, Huizhou, Nanchang
2024-10-18
Recruiting
argenx
Phase 3
69
Beijing, Bengbu, Chengde, Hohhot, Huai'an, Huizhou, Tianjin, Wuhan
2024-10-18
Recruiting
Bristol-Myers Squibb
Phase 3
1,000
Hefei, Beijing, Chongqing, Wanzhou, Fuzhou, Guangzhou, Huizhou, Liuzhou
2024-10-07
Recruiting
DK Medical Technology (Suzhou) Co., Ltd.
Not applicable
328
Hefei, Beijing, Chongqing, Guanzhou, Huizhou, Shenzhen, Liuzhou, Nanning
2024-09-30
Recruiting
Remote Ischemic Conditioning for Acute Ischemic Stroke Treated With Mechanical Thrombectomy（RECAST-MT）
NCT06559241Acute Ischemic Stroke, Anterior Circulation Brain Infarction
Capital Medical University
Phase 3
2,105
Suzhou, Taihe Chengguanzhen, Tongling, Beijing, Fuzhou, Zhangzhou, Heyuan, Huizhou
2024-09-23
Active, closed
Hoffmann-La Roche
Phase 3
400
Beijing, Binzhou, Changchun, Chengdu, Fuzhou, Guangzhou, Hefei, Huizhou
2024-09-17
Active, closed
Merck Sharp & Dohme LLC
Phase 3
3,000
Beijing, Chongqing, Guangzhou, Huizhou, Shenzhen, Jingzhou, Wuhan, Changsha
2024-08-05
Not yet open
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
420
Hefei, Fuzhou, Lanzhou, Guangzhou, Huizhou, Jiangmen, Meizhou, Guigang
2024-07
Active, closed
Guangzhou Medical University
Phase 1/2
45
Huizhou, Beijing, Shanghai
2024-06-30
Active, closed
SIM0718 Treatment of Asthma Clinical Study
NCT06488755Asthma; Eosinophilic
Simcere Pharmaceutical Co., Ltd
Phase 3
418
Hefei, Suzhou, Beijing, Chongqing, Lanzhou, Foshan, Guangzhou, Huizhou
2024-06-23
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Guangzhou, Huizhou
2024-06-05
Recruiting
Guangzhou Medical University
Not applicable
100
Huizhou
2024-04-18
Recruiting
Takeda
Phase 2
268
Chongqing, Xiamen, Guangzhou, Huizhou, Wuhan, Changsha, Changzhou, Suzhou
2024-03-05
Active, closed
Janssen Research & Development, LLC
Phase 2
305
Changzhou, Chengdoucun, Chengdu, Guangzhou, Hangzhou, Harbin, Huizhou, Nanjing
2024-02-16
Recruiting
Plasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral Mucositis
NCT06307314Nasopharyngeal Carcinoma, Head and Neck Cancer, Radiotherapy-induced Oral Mucositis, Biomarker
Nanfang Hospital, Southern Medical University
Observational
300
Guangzhou, Fuzhou, Huizhou, Jieyang, Meizhou
2024-02-01
Active, closed
DualityBio Inc.
Phase 3
228
Bengbu, Hefei, Beijing, Jilin City, Fuzhou, Xiamen, Guangzhou, Huizhou
2024-01-29
Recruiting
Tasly Pharmaceutical Group Co., Ltd
Phase 3
480
Beijing, Changsha, Chengdu, Haerbin, Huizhou, Kaifeng, Luoyang, Luzhou
2023-11-16
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,109
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Guangzhou, Huizhou
2023-10-25
Active, closed
Merck Sharp & Dohme LLC
Phase 3
14,550
Hefei, Beijing, Chongqing, Foshan, Guangzhou, Huizhou, Jiangmen, Shenzhen
2023-10-09
Recruiting
A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
NCT06064812Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer Stage IV, ER+/HER2- Breast Cancer
DrugFWD1802
Forward Pharmaceuticals Co., Ltd.
Phase 1/2
99
Hefei, Guangzhou, Huizhou, Nanning, Luoyang, Xinxiang, Zhengzhou, Wuhan
2023-09-12
Not yet open
Nanfang Hospital, Southern Medical University
Observational
2,592
Fuzhou, Dongguan, Guangzhou, Heyuan, Huizhou, Haikou, Changsha, Hengyang
2023-07-01
Recruiting
Takeda
Phase 3
408
Hefei, Wuhu, Beijing, Fuzhou, Lanzhou, Foshan, Guangzhou, Huizhou
2023-06-16
Recruiting
First Affiliated Hospital of Guangxi Medical University
Not applicable
190
Fuzhou, Guangzhou, Huizhou, Guilin, Liuzhou, Nanning, Wuzhou, Yulin
2023-06-12
Recruiting
Nanfang Hospital, Southern Medical University
Observational
2,592
Fuzhou, Dongguan, Guangzhou, Heyuan, Huizhou, Haikou, Changsha, Hengyang
2023-05-01
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
148
Huizhou, Nanyang, Lianyungang, Weihai, Tianjin
2023-04-12
Active, closed
Amgen
Observational
7,000
Beijing, Chongqing, Dongguan, Foshan, Guangzhou, Huizhou, Zhuhai, Guilin
2022-12-19
Active, closed
Amgen
Phase 3
7,297
Beijing, Guangzhou, Huizhou, Nanning, Daqing, Harbin, Nanyang, Wuhan
2022-12-14
Active, closed
Janssen Research & Development, LLC
Phase 1/2
57
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Huizhou, Shanghai, Shenyang
2022-12-13
Recruiting
Janssen Research & Development, LLC
Phase 2
520
Baoding, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Huizhou
2022-11-11
Active, closed
BeOne Medicines
Phase 3
799
Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Foshan, Guangzhou, Huizhou
2022-03-10
Active, closed
Janssen Research & Development, LLC
Phase 3
776
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Huizhou
2021-11-17
Active, closed
argenx
Phase 3
173
Beijing, Bengbu, Huizhou, Shenzhen, Tianjin, Wuhan, Wuxi, Zhengzhou
2021-11-17
Active, closed
Guangdong Provincial People's Hospital
Phase 3
440
Xiamen, Guangzhou, Huizhou, Jiangmen, Shenzhen, Zhanjiang, Nanning, Shangqiu
2021-08-12
Recruiting
Thrombus Aspiration in STEMI Patients With High Thrombus Burden
NCT04212494ST-segment Elevation Myocardial Infarction (STEMI)
Guangdong Provincial People's Hospital
Not applicable
3,838
Fuzhou, Foshan, Guangzhou, Huizhou, Jiangmen, Kaiping, Maoming, Shantou
2020-08-30
Recruiting
BeiGene
Phase 2
200
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Huizhou, Meizhou, Hechi
2018-09-19
Rows per page Showing 1–83 of 83
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 November 2026. https://priyalifescience.com/clinical-trials-china/city/huizhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,224 studies in total at the last sync on 11 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 83 of those studies with a site in Huizhou.

How many clinical trials are recruiting in Huizhou?

50 of the 83 studies on this page are recruiting new participants as of the 11 Nov 2026, 03:17 UTC sync. A further 8 have not yet opened recruitment, 25 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Huizhou), 83 studies
PhaseStudiesRecruitingShare
Phase 3361943.4%
Phase 2191522.9%
Phase 1/29410.8%
Not applicable859.6%
Observational738.4%
Phase 4222.4%
Phase 1111.2%
Phase 2/3111.2%

Most active sponsors

Lead sponsors with the most studies (Huizhou)
Lead sponsorStudiesRecruiting
Nanfang Hospital, Southern Medical University84
Guangzhou Medical University74
Hoffmann-La Roche53
Janssen Research & Development, LLC52
Merck Sharp & Dohme LLC51
Pfizer55
Eli Lilly and Company44
Sanofi43
Amgen30
argenx21
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.